The dominant model for managing pharmacy fraud at health insurers works like this: the pharmacy dispenses, the insurer pays, an audit team reviews a sample of claims weeks or months later, and when irregularities are found, initiates a recovery process that can take additional months or years. In the best case, the insurer recovers a fraction of what was lost. In the average case, losses are absorbed as operating cost.
This model has a structural problem that no amount of audit resources can solve: the money has already left. Every day that passes between payment and detection is a day the fraud scheme continues operating. And every recovery process has its own costs — legal, administrative, personnel — that reduce the net amount recovered.
Why post-payment audit does not scale
Post-payment audit has three fundamental limitations that make it inadequate as a primary control mechanism.
Insufficient coverage. No audit team can review 100% of claims. Audits operate on samples, and samples, by definition, do not capture everything. Coordinated fraud schemes, where each individual transaction appears normal, have a statistically low probability of being selected in a random sample. And targeted samples require selection criteria that presuppose knowing the fraud patterns before looking for them.
Latency. The time between payment and detection is irreducible in a post-payment model. Even with the best processes, weeks pass between payment and review. In practice, at many Latin American insurers, audit cycles are quarterly or semi-annual. A fraud scheme operating for six months before detection generates six months of irrecoverable losses.
Cost of recovery. Recovering fraudulent payments requires a process that frequently involves negotiation, arbitration, or litigation. The costs of this process — legal fees, personnel time, procedural costs — significantly reduce the net amount recovered. In many cases, especially for individually small amounts, the cost of recovery exceeds the amount to be recovered, causing the insurer to abandon the collection.
Our own regional data analyses confirm what these limitations produce in practice: 43.4% of pharmaceutical spend shows detectable anomalies. This is not an estimate of total fraud. It is the proportion of spend that exhibits anomalous patterns that post-payment audit, by design, is not capturing completely.
The real-time authorization model
The alternative is moving the control point from post-payment to pre-payment. Inspector AI evaluates every dispense event against dozens of detection rules before payment is authorized. The pharmacy submits the authorization request, the system evaluates the event against coverage rules, clinical protocols, utilization patterns, and anomaly signals, and responds with a real-time decision.
This is structurally different from post-payment audit in several ways.
Full coverage. Every dispensation is evaluated. There is no sampling. There are no transactions that pass without review. This eliminates the coverage gap that fraud schemes exploit.
Zero latency. Evaluation occurs at the moment of dispensation. There is no period of undetected operation. If an anomalous pattern emerges, the signal is generated immediately.
Prevention instead of recovery. When an anomaly is detected before payment, the payment does not occur. There is no amount to recover. There is no legal process. There is no recovery cost. The loss simply does not happen.
The Digital Dispense Contract
The underlying concept is what we call the Digital Dispense Contract (DDC). In this model, the medical prescription ceases to be a passive document that is filed after the fact and becomes an enforceable contract validated before the pharmacy dispenses.
The DDC establishes the terms of the dispensation: the authorized medication, the quantity, the permitted frequency, applicable clinical restrictions, and the patient's plan coverage rules. The pharmacy does not dispense until the DDC is validated. If the proposed dispensation does not comply with the contract terms — because the refill is early, because there is a clinical mismatch, because the medication has an available generic that should be substituted, or because the prescriber's pattern shows anomalies — the system flags the discrepancy before dispensation occurs.
CMS is also moving toward pre-payment prevention
The direction of the industry is consistent. The CMS CRUSH initiative (Centers for Medicare and Medicaid Services) in the United States is founded on the same principle: moving fraud detection from post-payment to pre-payment. The results reported by CMS — $2 billion in savings — are evidence that this approach produces results at scale.
The convergence between the CMS direction and Inspector AI's approach is not coincidental. The logic is the same: prevention is more efficient than recovery. The difference lies in implementation — CMS operates at the scale of a national system; Inspector AI operates at the scale of individual insurers — but the principle is identical.
The resistance to change
It is important to acknowledge why the post-payment model persists despite its evident limitations. There are organizational, technological, and provider-relationship reasons.
Organizationally, post-payment audit is an established process with defined roles, allocated budgets, and predictable (if modest) results. Moving to a pre-payment model requires reorganizing processes, redefining roles, and accepting a transition period.
Technologically, real-time authorization requires integration with pharmacy dispensing systems. This can be complex in markets with fragmented pharmacy networks and heterogeneous technology systems.
Regarding provider relationships, adding a control at the point of dispense can generate friction with pharmacies that perceive the control as an operational obstacle. This friction must be managed through progressive implementation and clear communication about the benefits for all ecosystem participants.
None of these obstacles is insurmountable. All are real and must be addressed in any implementation plan.
The arithmetic of prevention
Without projecting specific ROI numbers — which depend on each insurer's profile — the basic arithmetic of prevention vs. recovery is straightforward.
In the post-payment model, the cost of fraud is the amount paid minus the amount recovered, minus the cost of the recovery process. The recovered amount is a fraction of the paid amount, and the process cost reduces that fraction further.
In the pre-payment model, the cost of prevented fraud is the cost of operating the detection system. Prevented losses do not materialize, so there is no recovery to manage.
The market direction, validated by CMS at the scale of billions of dollars, indicates that pre-payment prevention is the model that will prevail. Insurers that adopt this model sooner will have an operational advantage over those that continue relying on post-payment audit.
To evaluate how real-time authorization can apply to your operation, request a free analysis.